Total Payments
$321,419
2024 Payments
$19,608
Companies
10
Transactions
322
Payment Breakdown by Category
Other$143,272 (44.6%)
Research$129,584 (40.3%)
Travel$38,443 (12.0%)
Consulting$8,500 (2.6%)
Food & Beverage$1,620 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $143,272 | 176 | 44.6% |
| Unspecified | $129,584 | 95 | 40.3% |
| Travel and Lodging | $38,443 | 18 | 12.0% |
| Consulting Fee | $8,500 | 4 | 2.6% |
| Food and Beverage | $1,620 | 29 | 0.5% |
Payments by Type
General
$191,835
227 transactions
Research
$129,584
95 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $294,365 | 280 | $0 (2024) |
| Genentech, Inc. | $10,771 | 14 | $0 (2024) |
| Novartis Pharma AG | $6,454 | 11 | $0 (2023) |
| ModernaTX, Inc. | $4,000 | 2 | $0 (2022) |
| Gilead Sciences, Inc. | $3,000 | 1 | $0 (2024) |
| Becton, Dickinson and Company | $1,500 | 1 | $0 (2023) |
| Genentech USA, Inc. | $1,118 | 9 | $0 (2022) |
| Roche Products Limited | $77.29 | 2 | $0 (2022) |
| LEICA MICROSYSTEMS INC. | $71.30 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $62.30 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,608 | 17 | F. Hoffmann-La Roche AG ($16,438) |
| 2023 | $19,982 | 17 | F. Hoffmann-La Roche AG ($15,692) |
| 2022 | $26,922 | 23 | F. Hoffmann-La Roche AG ($14,103) |
| 2021 | $33,541 | 24 | F. Hoffmann-La Roche AG ($29,738) |
| 2020 | $38,827 | 35 | F. Hoffmann-La Roche AG ($38,802) |
| 2019 | $51,765 | 57 | F. Hoffmann-La Roche AG ($51,591) |
| 2018 | $58,777 | 74 | F. Hoffmann-La Roche AG ($57,023) |
| 2017 | $71,996 | 75 | F. Hoffmann-La Roche AG ($70,977) |
All Payment Transactions
322 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $709.45 | Research |
| Study: Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years • Category: Immunology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $3,574.74 | Research |
| Study: Ocrelizumab vaccination study • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,915.00 | Research |
| Study: A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,488.42 | Research |
| Study: The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,488.42 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $602.81 | Research |
| Study: OCR PPMS EAP • Category: Immunology | ||||||
| 09/17/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $551.73 | General |
| Category: Immunology | ||||||
| 09/17/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $447.35 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Genentech, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $145.84 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $2,021.07 | Research |
| Study: Roll Over Protocol ROP for WA21092 OPERA I WA21093 OPERA II and WA25046 ORATORIO studies • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $939.48 | Research |
| Study: OCR PPMS EAP • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $848.23 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $753.99 | Research |
| Study: The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $469.73 | Research |
| Study: Circulating B-cell and serum neurofilament light chain levels associated with progressive disease outcomes in Phase III trials of ocrelizumab in people with relapsing or progressive multiple sclerosis • Category: Immunology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $628.05 | Research |
| Study: 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Efficacy and Safety Clinical Trial Data • Category: Immunology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $2,754.45 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,759.67 | Research |
| Study: Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis • Category: Immunology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,674.96 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 10/13/2023 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $32.52 | General |
| Category: Immunology | ||||||
| 10/11/2023 | Genentech, Inc. | — | Travel and Lodging | In-kind items and services | $207.89 | General |
| 10/11/2023 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $68.94 | General |
| 06/30/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $2,821.79 | Research |
| Study: A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis • Category: Immunology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,694.46 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis | F. Hoffmann-La Roche AG | $12,658 | 7 |
| Ocrelizumab in Patients with RMS | F. Hoffmann-La Roche AG | $10,922 | 8 |
| A RANDOMIZED, PLACEBO AND ACTIVE-CONTROLLED DOSE FINDING STUDY TO EVALUATE THE EFFICACY, AS MEASURED BY BRAIN MRI LESIONS, AND SAFETY OF 2 DOSE REGIMENS OF OCRELIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $9,596 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S | F. Hoffmann-La Roche AG | $9,284 | 7 |
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled | F. Hoffmann-La Roche AG | $7,887 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $5,321 | 5 |
| AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS OR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $5,035 | 10 |
| A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis | F. Hoffmann-La Roche AG | $4,737 | 2 |
| A PROSPECTIVE PILOT STUDY TO EVALUATE THE FEASIBILITY OF CONDUCTING REMOTE PATIENT MONITORING WITH THE USE OF DIGITAL TECHNOLOGY IN PATIENTS WITH MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $4,497 | 2 |
| LONG-TERM SUPPRESSION OF MRI DISEASE ACTIVITY AND REDUCTION OF GLOBALREGIONAL VOLUME LOSS RESULTS FROM OPERA III AND ORATORIO OPEN-LABEL EXTENSION | F. Hoffmann-La Roche AG | $4,344 | 4 |
| A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | F. Hoffmann-La Roche AG | $3,956 | 1 |
| Ocrelizumab vaccination study | F. Hoffmann-La Roche AG | $3,884 | 2 |
| Publication support research related | Novartis Pharma AG | $3,803 | 2 |
| NEURAL CORRELATES OF DIGITAL MEASURES SHOWN BY STRUCTURAL MRI A SMARTPHONE-BASED REMOTE ASSESSMENT FEASIBILITY STUDY IN MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $3,572 | 1 |
| COVID-19 IN PEOPLE WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB | F. Hoffmann-La Roche AG | $3,512 | 2 |
| SAFETY OF OCRELIZUMAB IN MULTIPLE SCLEROSIS LONG-TERM ADVERSE EVENT ANALYSES BASED ON INITIAL EXPOSURE QUARTILES | F. Hoffmann-La Roche AG | $3,027 | 2 |
| NEURAL CORRELATES OF HAND MOTOR FUNCTION REVEALED BY STRUCTURAL MR IMAGING A SMARTPHONE-BASED REMOTE ASSESSMENT STUDY IN PEOPLE WITH MS | F. Hoffmann-La Roche AG | $2,525 | 2 |
| COMB157G2301 | Novartis Pharma AG | $2,409 | 1 |
| The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies | F. Hoffmann-La Roche AG | $2,242 | 2 |
| COVID-19 RISK FACTORS IN PEOPLE WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB | F. Hoffmann-La Roche AG | $2,157 | 2 |
| Roll Over Protocol ROP for WA21092 OPERA I WA21093 OPERA II and WA25046 ORATORIO studies | F. Hoffmann-La Roche AG | $2,021 | 1 |
| A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to ongoing antidepressant treatment., A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study | F. Hoffmann-La Roche AG | $1,807 | 1 |
| COVID-19 IN PEOPLE WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB CLINICAL OUTCOMES IN VACCINATED PATIENTS | F. Hoffmann-La Roche AG | $1,793 | 2 |
| Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis | F. Hoffmann-La Roche AG | $1,760 | 1 |
| Time to walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis | F. Hoffmann-La Roche AG | $1,620 | 1 |
| A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MULTIPLE SCLEROSIS , A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,574 | 2 |
| Ocrelizumab in Patients with RMS, Second Phase III in RMS and Ocrelizumab in PPMS | F. Hoffmann-La Roche AG | $1,553 | 1 |
| OCR PPMS EAP | F. Hoffmann-La Roche AG | $1,542 | 2 |
| A Prospective Pilot Study to Evaluate the Feasibility of Conducting Remote Patient Monitoring With the Use of Digital Technology in Patients With Multiple Sclerosis | F. Hoffmann-La Roche AG | $1,518 | 1 |
| B-CELL SUBSET DEPLETION FOLLOWING OCRELIZUMAB TREATMENT IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,398 | 1 |
| Risk of wheelchair restriction in PPMS Data from the ORATORIO trial and the MSBase registry | F. Hoffmann-La Roche AG | $1,283 | 1 |
| Long-Term Efficacy of Ocrelizumab up to 8-Years in RMS Patients in the OPERA Study and Open-Label Extension Using Repeated Event Analysis | F. Hoffmann-La Roche AG | $1,207 | 1 |
| RISK OF REQUIRING A WALKING AID AFTER 6.5 YEARS OF OCRELIZUMAB TREATMENT IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS DATA FROM THE OPERA I AND OPERA II TRIALS | F. Hoffmann-La Roche AG | $1,073 | 1 |
| MNT OBOE | F. Hoffmann-La Roche AG | $1,008 | 1 |
| RISK OF REQUIRING A WHEELCHAIR IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS DATA FROM THE ORATORIO TRIAL AND THE MSBASE REGISTRY | F. Hoffmann-La Roche AG | $904.01 | 2 |
| Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years | F. Hoffmann-La Roche AG | $709.45 | 1 |
| 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Efficacy and Safety Clinical Trial Data | F. Hoffmann-La Roche AG | $628.05 | 1 |
| Circulating B-cell and serum neurofilament light chain levels associated with progressive disease outcomes in Phase III trials of ocrelizumab in people with relapsing or progressive multiple sclerosis | F. Hoffmann-La Roche AG | $469.73 | 1 |
| Ocrelizumab in Patients with RMS and Second Phase III in RMS | F. Hoffmann-La Roche AG | $346.48 | 1 |
About Dr. Stephen Hauser, M.D
Dr. Stephen Hauser, M.D is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700996931.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Hauser, M.D has received a total of $321,419 in payments from pharmaceutical and medical device companies, with $19,608 received in 2024. These payments were reported across 322 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($143,272).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology
- Location San Francisco, CA
- Active Since 08/30/2006
- Last Updated 06/16/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1700996931
Products in Payments
- OCREVUS (Biological) $225,156
- Ocrevus (Biological) $69,069
- Non-Covered Product (Drug) $10,794
- ARZERRA (Drug) $6,213
- OMB157G (Drug) $96.65
- Surgical Microscopes (Device) $71.30
- FTY720D (Drug) $63.00
- OMB157G_ARZERRA_HEMATOLOGY (Drug) $51.64
- FTD_GILENYA_NEUROSCIENCE (Drug) $30.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736